Alnylam Pharmaceuticals
NASDAQ:ALNYBiotechCambridge, MA, United States · Est. 2002 · 1,100 employees
Alnylam Pharmaceuticals is a biopharmaceutical company pioneering the development of RNA interference (RNAi) therapeutics for genetic disorders.
9
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
15
Indications↗
Distinct diseases across all programs
75
Clinical Trials↗
All sponsored trials (all statuses)
147
Orange Book Patents
Across 17 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
9 drugs in development
Approved1
Phase 34
Phase 24
Phase 11
Preclinical1
By Therapeutic Area
top 6
Cardiovascular
427%
Rare Disease
427%
Metabolic & Endocrine
213%
Hematology
17%
Oncology
17%
Neurology
17%
R&D Momentum
58/100
Pipeline Velocity
27/100
Trial Completion Rate
82/100
Pipeline Concentration
19/100
Pipeline Freshness
79/100
Strategic Signals
- ↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Jun 30, 2026TrialA Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ALN-6222 in Adult Participants With Obesity
Apr 30, 20268-KALNYLAM PHARMACEUTICALS, INC. (ALNY) (CIK 0001178670)
Mar 14, 2026TrialILLUMINATE-C: Givosiran in Pediatric AHP
Mar 12, 2026TrialHELIOS-B: Patisiran in Heart Failure with ATTR-CM
Mar 2, 2026TrialA Study to Evaluate ALN-2232 in Participants With Obesity
Feb 27, 2026FDACymbalta — DULOXETINE HYDROCHLORIDE
Jan 20, 2026TrialAPOLLO-B Extension: Patisiran in ATTR Cardiomyopathy
4 more events
Jan 16, 2026TrialTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Jan 15, 2026TrialA Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Dec 12, 2025TrialA Study to Evaluate ALN-4285 in Adult Healthy Volunteers
Oct 15, 2025TrialA Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
Details
Company Info
Company Overview
$15.0B
Mkt Cap
$492.9M
Revenue
$812.7M
Cash
CEOHelga Oberbauer
Founded2002
Employees1,100
HQCambridge, MA, United States
ExchangeNASDAQ:ALNY
Websitealnylam.com
LinkedInCompany Page
Therapeutic Focus
OncologyHematologyImmunologyOtherCardiovascularRare DiseaseNeurologyMetabolic & EndocrineInfectious DiseaseMusculoskeletalDermatologyGastroenterologyRespiratoryNephrologyOphthalmologyPsychiatry
Recent SEC Filings
8-KApr 30, 2026
ALNYLAM PHARMACEUTICALS, INC. (ALNY) (CIK 0001178670)
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Hematology
Metabolic & Endocrine
Oncology
Cardiovascular
Cardiomyopathy
NucresiranPhase 3
AmvuttraPhase 3
Heart Failure
OnpattroApproved
Hypertension
ZilebesiranPhase 2
Hematology
Amyloidosis
OnpattroPhase 2
Metabolic & Endocrine
Oncology
Rare Disease
Unknown / Other
Showing 15 of 19 programs
Regulatory
Regulatory Timeline
20182 events
FDANov 27
Acova — ARGATROBAN IN SODIUM CHLORIDE
Application NDA209552 (NDA)
FDAAug 10
Onpattro — ONPATTRO
Application NDA210922 (NDA)
20194 events
FDANov 27
Trexall — REDITREX
Application NDA210737 (NDA)
FDANov 20
Givlaari — GIVLAARI
Application NDA212194 (NDA)
FDAJul 19
Cymbalta — DRIZALMA SPRINKLE
Application NDA212516 (NDA)
FDAJan 30
Colcrys — GLOPERBA
Application NDA210942 (NDA)
20202 events
FDANov 23
Oxlumo — OXLUMO
Application NDA214103 (NDA)
FDAAug 24
Trexall — METHOTREXATE
Application NDA214121 (NDA)
20211 event
FDAJun 7
Acova — ARGATROBAN IN SODIUM CHLORIDE
Application NDA212035 (NDA)
20224 events
FDANov 29
Trexall — JYLAMVO
Application NDA212479 (NDA)
FDAJun 13
Amvuttra — AMVUTTRA
Application NDA215515 (NDA)
FDAApr 21
Robinul — GLYCOPYRROLATE
Application NDA214919 (NDA)
FDAJan 14
Plaquenil — SOVUNA
Application NDA214581 (NDA)
20233 events
FDAOct 11
Robinul — DARTISLA ODT
Application NDA215019 (NDA)
FDASep 8
Aphexda — APHEXDA
Application NDA217159 (NDA)
FDAJun 16
Colcrys — LODOCO
Application NDA215727 (NDA)
20241 event
FDAJun 25
Tepadina — TEPYLUTE
Application NDA216984 (NDA)
20252 events
FDAJul 23
Anzupgo — ANZUPGO
Application NDA219155 (NDA)
FDAMar 17
Thalitone — HEMICLOR
Application NDA218647 (NDA)
20262 events
SECApr 30
ALNYLAM PHARMACEUTICALS, INC. (ALNY) (CIK 0001178670)
Accession: 001-36407
FDAFeb 27
Cymbalta — DULOXETINE HYDROCHLORIDE
Application NDA219131 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)